{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:18:00Z","timestamp":1793049480523,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.msard.2023.104581","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T05:43:33Z","timestamp":1676526213000},"page":"104581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5268-4668","authenticated-orcid":false,"given":"Leonardo Zumerkorn","family":"Pipek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Vitor","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Farias Vidigal","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Lu\u00edsa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104581_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103115","article-title":"Early predictors of conversion to secondary progressive multiple sclerosis","volume":"54","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104581_bib0002","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2023.104581_bib0003","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104581_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12010119","article-title":"Escalation vs. early intense therapy in multiple sclerosis","volume":"12","author":"Casanova","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2023.104581_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103010","article-title":"Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"52","author":"Cree","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104581_bib0006","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","article-title":"Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0007","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104581_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0009","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104581_bib0012","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2023.104581_bib0014","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.msard.2023.104581_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004073","article-title":"UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model","volume":"4","author":"Palace","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2023.104581_bib0016","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104581_bib0017","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction versus escalation in multiple sclerosis: a 10-Year Real World Study","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2023.104581_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/WNF.0000000000000503","article-title":"Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina","volume":"45","author":"Rojas","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2023.104581_bib0019","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2023.104581_bib0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104581_bib0021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.msard.2023.104581_bib0022","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104581_bib0023","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2023.104581_bib0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/1352458517708687","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom","volume":"23","author":"Thompson","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104581_bib0025","article-title":"Evolution of Disease Modifying Therapy Benefits and Risks: an Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis","volume":"12","author":"Vollmer","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104581_bib0026","article-title":"Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:31Z","timestamp":1761901651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":26,"alternative-id":["S2211034823000858"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104581","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104581"}}